Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, compounding
Pharmacists “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of Wegovy and Ozempic.
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks,
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for those manufacturers to make safely.
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight loss and diabetes medications.
9h
on MSN
Ozempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.
13h
on MSN
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...
FiercePharma
1d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
“
Novo
Nordisk
’s aim with this nomination is to ensure that patients receive only FDA-approved, safe, and effective ...
BioSpace
1d
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
13h
Novo Nordisk’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...
3d
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
BioSpace
9h
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ozempic
Wegovy
Alzheimer's disease
Food and Drug Administration
Rybelsus
Feedback